RT Journal Article
SR Electronic
T1 Infectious viral shedding of SARS-CoV-2 Delta following vaccination: a longitudinal cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.15.22275051
DO 10.1101/2022.05.15.22275051
A1 Miguel Garcia-Knight
A1 Khamal Anglin
A1 Michel Tassetto
A1 Scott Lu
A1 Amethyst Zhang
A1 Sarah A. Goldberg
A1 Adam Catching
A1 Michelle C. Davidson
A1 Joshua R. Shak
A1 Mariela Romero
A1 Jesus Pineda-Ramirez
A1 Ruth Diaz Sanchez
A1 Paulina Rugart
A1 Kevin Donohue
A1 Jonathan Massachi
A1 Hannah M. Sans
A1 Manuella Djomaleu
A1 Sujata Mathur
A1 Venice Servellita
A1 David McIlwain
A1 Brice Gaudiliere
A1 Jessica Chen
A1 Enrique O. Martinez
A1 Jacqueline M. Tavs
A1 Grace Bronstone
A1 Jacob Weiss
A1 John T. Watson
A1 Melissa Briggs-Hagen
A1 Glen R. Abedi
A1 George W. Rutherford
A1 Steven G. Deeks
A1 Charles Chiu
A1 Sharon Saydah
A1 Michael J. Peluso
A1 Claire M. Midgley
A1 Jeffrey N. Martin
A1 Raul Andino
A1 J. Daniel Kelly
YR 2022
UL http://medrxiv.org/content/early/2022/05/19/2022.05.15.22275051.abstract
AB The impact of vaccination on SARS-CoV-2 infectiousness is not well understood. We compared longitudinal viral shedding dynamics in unvaccinated and fully vaccinated adults. SARS-CoV-2-infected adults were enrolled within 5 days of symptom onset and nasal specimens were self-collected daily for two weeks and intermittently for an additional two weeks. SARS-CoV-2 RNA load and infectious virus were analyzed relative to symptom onset stratified by vaccination status. We tested 1080 nasal specimens from 52 unvaccinated adults enrolled in the pre-Delta period and 32 fully vaccinated adults with predominantly Delta infections. While we observed no differences by vaccination status in maximum RNA levels, maximum infectious titers and the median duration of viral RNA shedding, the rate of decay from the maximum RNA load was faster among vaccinated; maximum infectious titers and maximum RNA levels were highly correlated. Furthermore, amongst participants with infectious virus, median duration of infectious virus detection was reduced from 7.5 days (IQR: 6.0-9.0) in unvaccinated participants to 6 days (IQR: 5.0-8.0) in those vaccinated (P=0.02). Accordingly, the odds of shedding infectious virus from days 6 to 12 post-onset were lower among vaccinated participants than unvaccinated participants (OR 0.42 95% CI 0.19-0.89). These results indicate that vaccination had reduced the probability of shedding infectious virus after 5 days from symptom onset.Significance statement We present longitudinal data on the magnitude, duration and decay rate of viral RNA and the magnitude and duration of infectious virus in nasal specimens from vaccinated and unvaccinated participants. On average, vaccinated participants (infected with the highly transmissible Delta variant) showed a lower probability of having infectious virus after 5 days of symptoms compared to unvaccinated participants (infected with mostly pre-delta viral lineages), even though both groups had a similar magnitude of infectious virus at or near the peak. These data help improve our understanding of the duration of the infectious period when infection occurs following vaccination and serves as a reference for future studies of shedding dynamics following infections with novel variants of concern.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Centers for Disease Control and Prevention Broad Agency Announcement. The National Institute of Allergy and Infectious Diseases also supported JDK during this study (K23 grant number AI146268), but this funding source had no role in the content of the manuscript nor the decision for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the University of California Institutional Review Board and given a designation of public health surveillance according to federal regulations as summarized in 45 CFR 46.102(d)(1)(2). Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors